Drug Exposure and Red-Cell Partitioning: Pharmacokinetic Mechanisms, Clinical Relevance, and Therapeutic Implications

Abstract

Red-cell partitioning is a clinically important but frequently underappreciated determinant of drug distribution, pharmacokinetic variability, pharmacodynamic response, and laboratory interpretation. The extent to which a drug enters erythrocytes depends on physicochemical properties, membrane transport, intracellular binding, carbonic anhydrase activity, hemoglobin interactions, hematocrit, disease state, and competing medicines. Red-cell distribution can alter whole-blood concentrations substantially compared with plasma concentrations and may influence apparent clearance, volume of distribution, tissue exposure, dialysis removal, and therapeutic drug monitoring. This review examines the mechanisms governing drug exposure in red blood cells, the clinical conditions and patient characteristics that modify partitioning, relevant diagnostic and management considerations, emerging analytical approaches, and practical recommendations for clinicians. Understanding red-cell pharmacokinetics is particularly important for drugs with narrow therapeutic indices, substantial erythrocyte accumulation, active intracellular metabolites, or concentration targets established from whole-blood rather than plasma measurements.

Introduction

Drug exposure is commonly assessed using plasma or serum concentrations, yet circulating blood is a heterogeneous biological compartment. Erythrocytes account for a major proportion of blood volume and provide a substantial intracellular space that can sequester, transport, metabolize, or release medicines. Red-cell partitioning describes the distribution of a drug between erythrocytes and plasma, often expressed through a red-cell to plasma concentration ratio. This ratio may remain stable for a particular compound under controlled conditions, but it can change with hematocrit, temperature, pH, protein binding, membrane integrity, transporter activity, and disease-associated alterations in erythrocyte composition.

The distinction between plasma exposure and whole-blood exposure is clinically relevant because pharmacokinetic studies, regulatory assessments, and therapeutic drug monitoring programs may use different biological matrices. A medicine that extensively partitions into red cells may show lower plasma concentrations despite substantial total blood exposure. Conversely, a compound that remains predominantly in plasma may be more strongly affected by albumin binding, plasma protein displacement, or changes in plasma volume. Failure to recognize these differences can result in incorrect dose adjustment, misinterpretation of apparent treatment failure, or inappropriate attribution of toxicity to altered clearance.

Epidemiology / Disease Burden

Red-cell partitioning is not a disease in itself, so conventional epidemiological estimates are not available. Its clinical burden arises from the large number of medicines for which blood-cell distribution contributes to exposure variability. This issue is especially relevant in infectious diseases, transplantation, oncology, neurology, cardiology, and critical care, where therapeutic drug monitoring and individualized dosing are frequently used. Antimalarial agents, antiretroviral drugs, immunosuppressants, antiepileptic medicines, and selected antimicrobials may demonstrate clinically meaningful differences between plasma and whole-blood concentrations.

The burden is amplified in populations with substantial hematological or physiological variation. Neonates, older adults, patients with severe anemia or polycythemia, individuals receiving extracorporeal support, and patients with renal or hepatic dysfunction may have exposure profiles that differ from those observed in healthy volunteers. In addition, inflammatory disease, oxidative stress, transfusion, hemolysis, and altered erythrocyte turnover can modify the cellular environment in which a drug is distributed. These factors may complicate interpatient comparisons and reduce the reliability of reference ranges developed in narrowly selected study populations.

Pathophysiology

Red-cell partitioning is governed initially by passive diffusion. Lipophilic, weakly basic, and moderately sized molecules often cross the erythrocyte membrane more readily than highly polar compounds. Once inside the cell, a drug may bind hemoglobin, membrane phospholipids, cytoskeletal proteins, or intracellular enzymes. Such binding can create a reversible intracellular reservoir and prolong apparent residence in blood. The intracellular pH and high concentration of hemoglobin may also promote ion trapping or specific binding, particularly for compounds with pH-dependent ionization.

Active transport further contributes to distribution. Erythrocytes express membrane proteins capable of facilitating or limiting drug entry and exit, although transporter expression and functional importance vary considerably among compounds. Some medicines may be substrates for equilibrative nucleoside transporters, organic anion or cation transport systems, or efflux mechanisms. Red-cell enzymes can also transform parent drugs or generate intracellular metabolites. Although erythrocytes lack nuclei and have limited synthetic capacity, they contain metabolically active pathways that may influence exposure for susceptible agents.

The red-cell to plasma ratio is affected by hematocrit because the measured whole-blood concentration represents a mixture of cellular and plasma compartments. A change in hematocrit may therefore alter whole-blood exposure even when the concentration within each compartment remains unchanged. Severe anemia can lower the cellular contribution to total blood concentration, whereas polycythemia may increase it. Changes in plasma protein binding can also shift distribution. When a drug is highly protein bound, displacement from plasma proteins may increase the unbound fraction available for red-cell uptake, while altered binding to hemoglobin or membrane components may produce the opposite effect.

Risk Factors

Important risk factors for clinically significant red-cell partitioning include marked anemia, polycythemia, hemoglobinopathies, hemolytic disorders, transfusion, renal failure, hepatic dysfunction, hypoalbuminemia, systemic inflammation, and major acid-base disturbances. Erythrocyte age distribution may be relevant because young and mature red cells differ in membrane composition, deformability, transporter activity, and intracellular enzyme content. Oxidative stress and membrane injury can change permeability and promote hemolysis, potentially releasing drugs or drug metabolites that were previously cell associated.

Drug-related risk factors include high lipophilicity, weak-base behavior, strong intracellular binding, active transport, long half-life, narrow therapeutic index, and a dosing strategy based on concentration targets. Drug combinations may modify red-cell exposure through metabolic inhibition, transporter competition, altered protein binding, or changes in hematological status. Extracorporeal membrane oxygenation, hemodialysis, and other blood-contacting devices may additionally influence cellular distribution through adsorption, shear stress, dilution, and changes in hematocrit.

Clinical Features

Patients do not experience symptoms from red-cell partitioning itself; clinical manifestations result from altered total or unbound drug exposure. Excessive exposure may produce concentration-dependent toxicity, such as neurotoxicity, bleeding, arrhythmia, nephrotoxicity, hepatotoxicity, or marrow suppression, depending on the medicine. Inadequate exposure may manifest as persistent infection, rejection after transplantation, breakthrough seizures, uncontrolled inflammation, or disease progression. A discrepancy between clinical response and plasma concentration should prompt consideration of cellular distribution, adherence, sampling time, assay methodology, and pharmacogenetic variation.

For some agents, erythrocyte accumulation may prolong pharmacological effects after plasma concentrations have declined. This can be beneficial when it provides sustained intracellular activity, but it can also delay recovery from toxicity. Conversely, a low plasma concentration may not indicate insufficient tissue exposure if the drug is efficiently transferred into cells or target tissues. Clinical assessment must therefore integrate symptoms, treatment response, organ function, timing of sampling, and the matrix used for concentration measurement.

Diagnosis

Evaluation begins with a careful review of the pharmacokinetic characteristics of the medicine and the laboratory matrix used for monitoring. Clinicians should determine whether published therapeutic ranges refer to plasma, serum, or whole blood and should avoid directly comparing values obtained from different matrices. When clinically justified, paired plasma and whole-blood samples can help identify a high or changing red-cell to plasma ratio. Sampling should be standardized with respect to dose timing, steady-state status, temperature handling, anticoagulant, and processing interval.

Laboratory measurement may use liquid chromatography coupled with tandem mass spectrometry, validated immunoassays, or other compound-specific techniques. Analytical methods should demonstrate recovery from both plasma and cellular fractions because incomplete cell lysis or delayed separation can create systematic error. Hematocrit should be recorded alongside concentration results, particularly when whole-blood exposure is used for dose adjustment. In research and specialized clinical settings, fractionation studies, incubation experiments, transporter assays, and physiologically based pharmacokinetic modeling can clarify the mechanism of unusual exposure patterns.

Treatment & Management

Management is individualized and should focus on the clinical objective rather than an isolated concentration value. When a medicine is known to partition substantially into erythrocytes, clinicians should use the validated matrix-specific therapeutic range and avoid converting plasma values to whole-blood values with an unverified formula. Dose changes should generally be conservative, especially when the drug has a long half-life, delayed intracellular release, or a narrow safety margin. Repeat monitoring after a dose adjustment should allow adequate time to approach the relevant steady state.

Hematocrit, renal function, hepatic function, albumin concentration, inflammatory status, and interacting medicines should be assessed when exposure changes unexpectedly. In anemia or polycythemia, whole-blood concentrations may shift because of altered cellular volume, and interpretation may require pharmacokinetic consultation. For toxicity, supportive care and standard antidotal or elimination strategies remain central, but clinicians should recognize that red-cell sequestration may delay decline in circulating or pharmacologically active concentrations. Dialysis efficacy cannot be inferred solely from plasma protein binding because cellular distribution and rebound release may limit removal.

Recent Advances / Emerging Therapies

Recent advances emphasize integrated pharmacokinetic modeling rather than reliance on a single blood compartment. Population pharmacokinetic models increasingly incorporate hematocrit, albumin, kidney function, inflammation, and transporter-related covariates. Physiologically based models can represent plasma, erythrocyte, and tissue compartments and may improve dose prediction in populations underrepresented in clinical trials. Dried blood spot and microsampling technologies are also being refined, although their validity depends on hematocrit correction, uniform cellular distribution, and compound-specific recovery.

Analytical research is progressing toward simultaneous quantification of parent drugs, active metabolites, and unbound fractions in plasma and erythrocytes. Cellular pharmacology may permit better identification of intracellular targets and explain why total blood exposure does not always correlate with response. Future therapeutic strategies may include formulations or prodrugs designed to optimize erythrocyte delivery for infections and malignancies, while minimizing unwanted cellular accumulation for drugs associated with delayed toxicity. These approaches require careful evaluation of red-cell safety, release kinetics, and interindividual variability.

Guideline Recommendations

Guidance for clinicians can be summarized in several principles. First, use the biological matrix specified in the validated assay and therapeutic range. Second, document hematocrit and relevant organ function when interpreting whole-blood concentrations. Third, obtain samples at standardized times and confirm adherence, dose history, and steady-state conditions. Fourth, interpret concentrations together with clinical response and toxicity rather than applying automatic dose changes. Fifth, seek pharmacology or laboratory expertise when plasma and whole-blood results appear discordant, when hematocrit changes substantially, or when extracorporeal support is present.

Drug development programs should characterize red-cell partitioning early, report both plasma and whole-blood pharmacokinetics when clinically relevant, and evaluate the effect of demographic, hematological, and disease-related covariates. Therapeutic drug monitoring protocols should specify matrix, assay, sampling time, handling requirements, and target range. These practices improve comparability across studies and reduce avoidable dosing errors.

Conclusion

Red-cell partitioning is a fundamental component of drug disposition that can materially alter measured exposure, pharmacological effect, toxicity risk, and therapeutic drug monitoring. Its clinical importance is greatest for medicines with substantial intracellular binding, active transport, narrow therapeutic indices, or concentration targets established in whole blood. Hematocrit, erythrocyte integrity, protein binding, organ dysfunction, inflammation, and interacting therapies can all modify cellular distribution. Accurate interpretation requires matrix-specific assays, standardized sampling, awareness of patient-specific risk factors, and integration of pharmacokinetic data with clinical outcomes. Incorporating erythrocyte pharmacokinetics into routine drug development and individualized treatment will improve dose selection and strengthen the safety and effectiveness of precision pharmacotherapy.